Exicure Inc

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes.

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results.

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“Panel”) granted an extension to continue the Company's listing subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by November 14, 2024. The Company is diligently working to timely satisfy the terms of the Panel's requests and to ensure.

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation.

Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company expects that the Reverse Stock Split will become effective at 5:00 pm on Tuesday, August 27, 2024, and its common stock will begin trading on a split-adjusted basis at the open of trading on Wednesday, August 28, 2024 under the new CUSIP number 30205M 309. Exicure's common stock.

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting.

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting.

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2024 Financial Results.

Exicure, Inc. Reports Second Quarter 2024 Financial Results

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics.

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Receives Positive Listing Determination from Nasdaq.

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Exicure (NASDAQ: XCUR ) stock is dropping on Monday after the prior early-stage pharmaceutical company's shares underwent a rally on Friday. That rally resulted in shares of XCUR stock rising 76% higher during normal trading hours.

Why Is Exicure (XCUR) Stock Down 27% Today?

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. First Quarter 2024 Finan.

Exicure, Inc. Reports First Quarter 2024 Financial Results

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Reports Full Year 2023 Financial Results.

Exicure, Inc. Reports Full Year 2023 Financial Results

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the “Staff Delisting Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”). The Staff Delisting Determination notified the Company that since it has not yet filed its Form 10-K for the year ended December 31, 2023 (the “Form 10-K”) per Nasdaq Listing Rule 5250(c)(1) (the “Rule”) by Nasdaq's extended d.

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. Third Quarter 2023 Financial Results Ca.

Exicure, Inc. Reports Third Quarter 2023 Financial Results

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on April 17, 2024 notifying the Company that, as a result of the Company's failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies to timely file all.

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

CHICAGO--(BUSINESS WIRE)--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. ("Bluejay") and Exicure, Inc. ("Exicure") entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis. Under the terms of the agreement, Bluejay will receive an exclusive l.

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Exicure (NASDAQ: XCUR ) stock is rising higher on Friday despite a lack of news from the early-stage biotechnology company. Exicure hasn't released any recent press releases or made any filings that would result in today's stock rally.

Why Is Exicure (XCUR) Stock Up 57% Today?

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on November 22, 2023 notifying the Company that, as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies.

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. announces appointment of new CEO and CFO and changes to Board of Directors.

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. reports second quarter 2023 financial results and provides corporate update.

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. reports first quarter 2023 financial results and provides corporate update.

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic alternatives to maximize stockholder value, and as part of such ongoing effort, previously announced the appointment of Jung Sang (Michael) Kim as Chief Executive Officer and Chief Financial Officer of t.

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

CHICAGO--(BUSINESS WIRE)--Exicure has invested in Cyworld Z Co. Ltd. through the purchase of $1 million aggregate principal amount of convertible bonds issued by Cyworld Z.

News for Exicure Inc Stock (XCUR)